A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
- Indications Crohn's disease
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2018 Status changed from not yet recruiting to recruiting.
- 02 Feb 2018 Planned initiation date changed from 8 Jan 2018 to 2 Feb 2018.